Longitudinal systemic therapy of plaque psoriasis: a literature review with a case report of use of ixekizumab


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Currently, psoriasis is considered as a chronic systemic inflammatory disease with an immunogenetic basis. Plaque psoriasis is the most common form, and the tactics of its treatment management depends on the severity of the disease. The discovery of the role of the immune system in the pathogenesis of psoriasis contributed to the initiation of the use of a number of systemic agents characterized by insufficient efficacy and tolerance. The extension of the knowledge base on pathogenesis has made it possible to introduce highly effective and safe drugs into clinical practice. Despite this, less specific drugs are still widely used in the treatment of moderate to severe psoriasis. Chronic course, significant impact on the quality of life and association with a number of comorbid conditions determine high requirements for long-term therapy of psoriasis. Among a wide range of systemic drugs, the greatest compliance with these requirements is demonstrated by genetically engineered biological drugs aimed at suppressing interleukin-17(IL-17) and IL-23. While traditional systemic drugs have many years of experience, there is little information available for IL-17 and IL-23 blockers. Our clinical case shows that the use of ixekizumab in the treatment of severe psoriasis vulgaris for 68 weeks remains a safe and highly effective therapy

Толық мәтін

Рұқсат жабық

Авторлар туралы

K. Fomin

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; M.F. Vladimirsky Moscow Regional Research Clinical Institute

Moscow, Russia

N. Merzlikina

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation

Moscow, Russia

S. Zhufina

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation

Moscow, Russia

Elena Svechnikova

Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical University

Email: elene-elene@bk.ru
Dr. Sci. (Med.), Head of the Department of Dermatovenereology and Cosmetology, Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; Professor at the Department of Dermatovenereology and Cosmetology, Novosibirsk State Medical University Moscow, Russia

Әдебиет тізімі

  1. Schön M.P Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol. 2019;10:1764. Doi: 10.3389/ fimmu.2019.01764.
  2. Yasmeen N, Sawyer L.M., Malottki K., et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatol Treat. 2020 Apr 2:1-15. doi: 10.1080/09546634.2020.1743811.
  3. Benezeder T., Wolf P Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin Immunopathol. 2019;41(6):633-doi: 10.1007/s00281-019-00766-z.
  4. Arnone M., Takahashi M.D.F., Carvalho A.V.E., et al. Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. Ann Bras Dermatol. 2019;94(2 Suppl. 1):76-107. doi: 10.1590/abd1806-4841.2019940211.
  5. Gisondi P., Bellinato F., Girolomoni G., Albanesi C. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Front Pharmacol. 2020;11:117. Doi: 10.3389/ fphar.2020.00117.
  6. Boehncke W.H. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579.
  7. Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS. 2019;127(5):386-424. doi: 10.1111/apm.12934.
  8. Hawkes J.E., Yan B.Y, Chan T.C., Krueger J.G. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605-13. Doi: 10.4049/ jimmunol.1800013.
  9. Brembilla N.C., Senra L., Boehncke W.H. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018;9:1682. doi: 10.3389/fimmu.2018.01682.
  10. Balak D.M.W., Gerdes S., Parodi A., Salgado-Boquete L. Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature. Dermatol Ther. (Heidelb). 2020;10(4):589-613. doi: 10.1007/s13555-020-00409-4.
  11. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М., 2016.
  12. Volc S., Ghoreschi K. Pathophysiological basis of systemic treatments in psoriasis. J Dtsch Dermatol Ges. 2016;14(6):557-72. Doi: 10.1111/ ddg.13050.
  13. Amber T, Tabassum S. Cyclosporin in dermatology: A practical compendium. Dermatol Ther. 2020;33(6):e13934. doi: 10.1111/dth.13934.
  14. Flores C., Fouquet G., Moura I.C., et al. Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications. Front Immunol. 2019;10:588. Doi: 10.3389/ fimmu.2019.00588.
  15. Goldenberg G., Lanoue J., Dong J. New Oral Therapies for Psoriasis: A Comprehensive Review. J Clin Aesthet Dermatol. 2016;9(8):25-8.
  16. Colombo M.D., Cassano N., Bellia G., Vena G.A. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. Sci World J. 2013;2013:805705. doi: 10.1155/2013/805705.
  17. Kerdel F., Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390-403. doi: 10.1111/dth.12267.
  18. Mikhaylov D., Hashim P.W., Nektalova T., Goldenberg G. Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. J Clin Aesthet Dermatol. 2019;12(6):46-54.
  19. Czarnecka-Operacz M., Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol. Alergol. 2014;31(6):392-400. doi: 10.5114/pdia.2014.47121. [Epub 2014 Dec 3]. PMID: 25610355; PMCID: PMC4293394.
  20. Dubertret L. Retinoids, methotrexate and cyclosporine. Curr Probl Dermatol. 2009;38:79-94. doi: 10.1159/000232305.
  21. Armstrong A.W., Aldredge L., Yamauchi P.S. Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. J Cutan Med Surg. 2016;20(3):196-206. doi: 10.1177/1203475415623508.
  22. Kim W.B., Jerome D., Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-85.
  23. Vena G.A, Cassano N., iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018;14:105-16. doi: 10.2147/TCRM. S154745.
  24. Puscas A.D., Catana A., Puscas C., et al. Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment. Exp Ther Med. 2019;18(2):875-80. Doi: 10.3892/ etm.2019.7624.
  25. Menter A., Gelfand J.M., Connor C., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-86. Doi: 10.1016/j. jaad.2020.02.044.
  26. Booij M.T., VanDeKerkhof P.C. Acitretinrevisitedinthe era of biologics. J Dermatol Treat. 2011;22(2):86-doi: 10.3109/09546630903578582.
  27. Tokuyama M., Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci. 2020;21(20):7488. Doi: 10.3390/ ijms21207488.
  28. Sawyer L.M., Malottki K., Sabry-Grant C., et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS One. 2019;14(8):e0220868. doi: 10.1371/journal. pone.0220868.
  29. Ronholt K., Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017;18(11):2297. Doi: 10.3390/ ijms18112297.
  30. Ten Bergen L.L., Petrovic A., Krogh Aarebrot A., Appel S. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946. doi: 10.1111/sji.12946.
  31. Brownstone N.D., Hong J., Mosca M., et al. Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics. 2021;15:39-51. doi: 10.2147/BTT.S252578.
  32. Leonardi C.L., Powers J.L., Matheson R.T, et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014-22. Doi: 10.1056/ NEJMoa030409.
  33. Gordon K., Papp K., Poulin Y., et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241-51. Doi: 10.1016/j. jaad.2010.12.005.
  34. Subedi S., Gong Y., Chen Y., Shi Y. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events. Drug Des Devel Ther. 2019;13:2491-502. doi: 10.2147/DDDT. S200147.
  35. Lin P.T., Wang S.H., Chi C.C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. doi: 10.1038/s41598-018-34293-y.
  36. Gerriets V., Bansal P., Goyal A., Khaddour K. Tumor Necrosis Factor Inhibitors. 2020 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2021 Jan.
  37. Yang K., Oak A.S.W., Elewski B.E. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol. 2021;22(2):173-92. doi: 10.1007/s40257-020-00578-0.
  38. Sbidian E., Chaimani A., Garcia-Doval I., et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535. doi: 10.1002/14651858.CD011535. pub2. Update in: Cochrane Database Syst Rev. 2020;1:CD011535.
  39. Reich K., Gooderham M., Bewley A., et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402. doi: 10.1111/jdv.14738.
  40. Mahil S.K., Capon F., Barker J.N. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11-27. doi: 10.1007/s00281-015-0539-8.
  41. Kimmel G., Chima M., Kim H.J., et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857-59. Doi: 10.1016/j. jaad.2019.05.007.
  42. Blauvelt A., Papp K.A., Merola J.F., et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebocontrolled, phase 2b extension study J Am Acad Dermatol. 2020;83(5):1367-74. Doi: 10.1016/j. jaad.2020.05.105.
  43. Саввина Н.А., Слепцова Н.П., Стешенко И.Г. Опыт применения отечественного ингибитора К-17А (anti-IL-17А) в терапии среднетяжелого псориаза. Клиническая дерматология и венерология. 2020;19(5):727-36
  44. Balogh E.A., Bashyam A.M., Ghamrawi R.I., Feldman S.R. Emerging systemic drugs in the treatment of plaque psoriasis. Expert. Opin Emerg. Drugs. 2020;25(2):89-100. doi: 10.1080/14728214.2020.1745 773.
  45. von Stebut E., Boehncke W.H., Ghoreschi K., et al. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Front Immunol. 2020;10:3096. Doi: 10.3389/ fimmu.2019.03096.
  46. Light J.G., Su J.J., Feldman S.R. Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Cosmet Investig Dermatol. 2021;14:55-63. doi: 10.2147/CCID. S235242.
  47. Wechter T, Cline A., Feldman S.R. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag. 2018;14:1489-97. doi: 10.2147/TCRM. S177127.
  48. Yang E.J., Smith M.P., Ly K., Bhutani T. Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis. Drug Des Devel Ther. 2019;13:1993-2000. doi: 10.2147/DDDT. S137588.
  49. Kamata M., Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020;21(5):1690. doi: 10.3390/ijms21051690.
  50. Bissonnette R., Luger T., Thaci D., et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-14. doi: 10.1111/jdv.14878.
  51. Pinter A., Bonnekoh B., Hadshiew I.M., Zimmer S. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Invest Dermatol. 2019;12:509-17. doi: 10.2147/CCID.S211938.
  52. Pithadia D.J., Reynolds K.A., Lee E.B., et al. Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. Ther Adv Chron Dis. 2019;10:2040622319865658. doi: 10.1177/2040622319865658.
  53. Reich K., Rich P., Maari C., et al. AMAF investigators. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study. Br J Dermatol. 2019;181(1):88-95. doi: 10.1111/bjd.17628.
  54. Giunta A., Ventura A., Chimenti M.S., et al. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther. 2017;11:1643-51. doi: 10.2147/DDDT. S92128.
  55. Leonardi C., Reich K., Foley P., et al. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther. (Heidelb). 2020;10(3):431-47. Doi: 10.1007/ s13555-020-00367-x.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>